


**Product Name** : WC522  
**Cat. No.** : PC-24367  
**CAS No.** :  
**Molecular Formula** : C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>  
**Molecular Weight** : 380.53  
**Target** : Dishevelled  
**Solubility** : 10 mM in DMSO



### Biological Activity

WC522 is a selective small molecule inhibitor of **Dvl2-PDZ-cholesterol** interaction, effectively suppresses both **Wnt**-independent and Wnt-stimulated  $\beta$ -catenin signaling activity in Dvl2-expressing APC-truncated CRC cells.

WC522 occupies the region where Dvl2-PDZ interacts with cholesterol molecules in the membrane.

WC522B (biotinylated derivative of WC522) captured Dvl2 but not Dvl1 and Dvl3 in both HCT15 and HCT116 cells

WC522 dose-dependently inhibits HCT15 cell viability and induces cell apoptosis.

WC522 potently inhibits  $\beta$ -catenin stability and  $\beta$ -catenin transcriptional activity in HCT15 and Caco2 cells, WC522 also suppresses  $\beta$ -catenin signaling in DLD1 and LOVO cells.

WC522 is effective against all Dvl-expressing APC-truncated CRC cells regardless of the length of the truncated APC.

WC522 blocks cell proliferation of APC-truncated CRC cells, with little to no antiproliferative effect against normal colon epithelial (CCD-18Co) cells, induces apoptosis of APC-truncated CRC cells.

WC522 (200 mg/kg, subcutaneous injection) blocks CRC tumors HCT15 xenografts in mice and effectively suppresses the level of active  $\beta$ -catenin, does not inhibit tumor growth of Dvl2-KO HCT15 xenografts.

### References

Sharma A, et al. *Nat Chem Biol*. 2025 Apr 16. doi: 10.1038/s41589-025-01870-y.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com